Abstract 1077: Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential

@inproceedings{Morelli2016Abstract1T,
  title={Abstract 1077: Targeting oncogenic miR-17-92 primary transcripts by LNA gapmeRs in multiple myeloma: Molecular findings and therapeutic potential},
  author={Eugenio Morelli and Lavinia Biamonte and Cinzia Federico and Maria Teresa Di Martino and Nicola Amodio and Maria Eugenia Gallo Cantafio and Niels Morten Marslev Frandsen and Maria Rita Pitari and Daniele Caracciolo and Annamaria Gull{\`a} and Marco Rossi and Pierosandro Tagliaferri and Pierfrancesco Tassone},
  year={2016}
}
There is emerging evidence that miR-17-92 plays a crucial role in c-Myc driven tumorigenesis of multiple myeloma (MM). We attempted to antagonize its full-oncogenic activity by targeting primary transcripts (pri-miR-17-92) with RNase H-triggering antisense oligonucleotides (LNA gapmeRs). Specifically, 7 different molecules were generated and screened for their ability to inhibit pri-miR-17-92 expression. The most effective molecule, henceforth named miR17-92-i-PT, was selected for furher… CONTINUE READING